Confluence Investment Management LLC Increases Position in Natus Medical Incorporated (NASDAQ:NTUS)

Share on StockTwits

Confluence Investment Management LLC grew its holdings in shares of Natus Medical Incorporated (NASDAQ:NTUS) by 14.4% in the 1st quarter, Holdings reports. The firm owned 175,277 shares of the company’s stock after acquiring an additional 21,998 shares during the period. Confluence Investment Management LLC’s holdings in Natus Medical were worth $4,488,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Veriti Management LLC bought a new position in Natus Medical in the 4th quarter worth about $40,000. Nisa Investment Advisors LLC bought a new position in Natus Medical in the 4th quarter valued at approximately $50,000. Seizert Capital Partners LLC bought a new position in Natus Medical in the 4th quarter valued at approximately $237,000. ExodusPoint Capital Management LP purchased a new stake in Natus Medical during the 3rd quarter valued at $248,000. Finally, Squarepoint Ops LLC increased its holdings in shares of Natus Medical by 5.2% in the 4th quarter. Squarepoint Ops LLC now owns 12,535 shares of the company’s stock worth $251,000 after purchasing an additional 624 shares in the last quarter. 89.67% of the stock is currently owned by hedge funds and other institutional investors.

Shares of NTUS traded down $0.26 during mid-day trading on Thursday, reaching $25.21. The stock had a trading volume of 138,794 shares, compared to its average volume of 185,645. The firm has a market cap of $853.96 million, a price-to-earnings ratio of -45.84 and a beta of 0.72. Natus Medical Incorporated has a 12 month low of $16.38 and a 12 month high of $27.97. The business has a fifty day moving average of $25.79 and a 200 day moving average of $22.33. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.41 and a current ratio of 2.02.

Natus Medical (NASDAQ:NTUS) last issued its quarterly earnings results on Thursday, February 25th. The company reported $0.39 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.15. Natus Medical had a positive return on equity of 3.87% and a negative net margin of 4.33%. On average, research analysts forecast that Natus Medical Incorporated will post 0.25 EPS for the current fiscal year.

NTUS has been the topic of several recent analyst reports. Zacks Investment Research raised Natus Medical from a “hold” rating to a “strong-buy” rating and set a $30.00 price objective on the stock in a research report on Tuesday, March 2nd. TheStreet upgraded shares of Natus Medical from a “d+” rating to a “c-” rating in a research note on Wednesday, January 6th.

Natus Medical Company Profile

Natus Medical, Inc provides medical device solutions focuses on the diagnosis and treatment of central nervous and sensory system disorders for patients of all ages. Its products are used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Featured Story: How to calculate the annual rate of depreciation

Want to see what other hedge funds are holding NTUS? Visit to get the latest 13F filings and insider trades for Natus Medical Incorporated (NASDAQ:NTUS).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:NTUS)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with's FREE daily email newsletter.